Compare Amphastar Pharmaceuticals Inc (AMPH) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs FedEx Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while FedEx Corporation trades at $321.78 (market cap $75.37B). The key difference: FedEx Corporation is far larger — about 87.2× Amphastar Pharmaceuticals Inc's market cap, and FedEx Corporation pays a 1.53% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | FDX | |
|---|---|---|
Market Cap | $863.95M | $75.37B |
Sector | Health | Industrials |
52-Week High | $30.81 | $338.75 |
52-Week Low | $16.87 | $180.51 |
Enterprise Value | $1.26B | $105.00B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
FedEx (FDX) trades at $318.57, up 0.85% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with a P/E of 17.17 and net income margin of 4.68%, supported by recent earnings beats. Network transformation initiatives and premium revenue mix are driving operational improvements, while analyst consensus remains strongly positive with a $360.27 price target.
Outlook remains favorable with projected revenue growth to $94.7B in 2026 and continued margin expansion. Key risks include competitive pressures in logistics and macroeconomic sensitivity. The stock offers value with reasonable valuation metrics and strong institutional support, though investors should monitor execution of cost-saving initiatives and freight demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
